Adial Pharmaceuticals Commends Bipartisan Legislation Supporting Emerging AUD Therapies for Veterans

Adial Pharmaceuticals commends Congress on introducing bipartisan legislation, the Expanding Veterans' Access to Emerging Treatments Act, which aims to expand research and development of emerging therapies for conditions affecting US veterans, including Alcohol Use Disorder (AUD). The bill includes AUD among eligible conditions and supports non-abstinence based treatment options. Adial's lead investigational product candidate, AD04, is a genetically targeted therapy for AUD that follows a non-abstinence based treatment approach.